Quality of life in patients with neurofibromatosis type 1 and 2 in Canada

Geohana Hamoy-Jimenez, Raymond Kim, Suganth Suppiah, Gelareh Zadeh, Vera Bril, and Carolina Barnett

Division of Neurology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada (G.H.-J., V.B., C.B.); Division of Medical Oncology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada (R.K.); Division of Neurosurgery, Department of Surgery, University Health Network and University of Toronto, Toronto, Ontario, Canada (S.S., G.Z.); Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada (C.B.)

Corresponding Author: Carolina Barnett, MD, PhD, Department of Medicine, Division of Neurology. University Health Network, 200 Elizabeth St., 5EC Room 334, Toronto, ON M5G 2C4, Canada (c.barnettapia@utoronto.ca).

Abstract

Background. There is scarce data on the quality of life of people with neurofibromatosis type 1 (NF1) and type 2 (NF2) in Canada.

Methods. A cross-sectional study of adults with NF1 and NF2 attending a tertiary center. Patients completed generic measures (SF-36, EQ-5D-5L, and PROMIS pain interference) and disease-specific questionnaires (PedsQL NF1 module and the NFTI-QOL for NF2). We compared generic scores between NF1 and NF2 individuals and used regression models to assess factors associated with quality of life.

Results. Hundred and eighty-four participants were enrolled. Mean age was 33 years in NF1 and 40 years in NF2. NF1 and NF2 individuals had lower employment rates and lower scores in all domains of the SF-36 compared to the general Canadian population ($P < .005$). Using the EQ-5D-5L, there was a high proportion of pain (64% in NF1 and 74% in NF2) and anxiety/depression (60% in NF1 and 68% in NF2). Pain interference correlated with poor quality of life in NF1 and NF2; perceived physical appearance was the main predictor of mental well-being in NF1.

Conclusions. Individuals with NF1 and NF2 have low quality of life, and this correlates with pain, anxiety, and depression, which are prevalent in NF1 and NF2. Perceived physical appearance predicts quality of life in NF1. A multidisciplinary approach is necessary for patients with NF1 and NF2, including mental health and pain management.

Key Points

- People with NF1 and NF2 have worse quality of life than the general Canadian population.
- Pain, anxiety, and depression are common in individuals with NF1 and NF2.
- Mental health and pain care are important aspects of care for people with NF1 and NF2.

Neurofibromatosis type 1 (NF1) and type 2 (NF2) are hereditary, tumor predisposition syndromes that affect multiple systems. NF1, caused by pathogenic variants in the NF1 gene, is characterized by café au lait macules, skin-fold freckling, Lisch nodules, optic glioma, and bone deformities. In addition, NF1 patients are prone to developing innumerable peripheral nerve sheath tumors. Cutaneous neurofibromas, while benign, have significant psychosocial implications due to itchiness, physical disfigurement, and sometimes pain. Similarly, plexiform neurofibromas often cause pain, deformity, and can also develop into a highly aggressive sarcoma called malignant peripheral nerve sheath tumors (MPNSTs).1
Patients with NF2 typically develop bilateral acoustic schwannomas, as well as schwannomas on other nerves, meningiomas, and early cataracts. Clinically, these manifest with symptoms such as progressive hearing and visual loss, facial weakness, balance and mobility impairments, and pain. These patients harbor pathogenic variants in the NF2 gene.

Health-related quality of life (QoL) is a complex multidimensional construct that depends on biological and psychological variables, symptoms, functional status, general health perceptions, and the influences of personal (eg, individual preferences) and environmental factors (eg, social support), as well as nonmedical factors. The clinical manifestations of NF1 and NF2 have profound effects and limitations on daily life activities, social roles, and mental health. As a result, it is not surprising that affected individuals may have poor QoL. Several studies using generic and disease-specific measures have shown reduced QoL among patients with NF1. Disease visibility and whole-tumor burden have been recognized as major predictors of poor QoL in NF1, as well as pain interference in young patients with NF1 and plexiform neurofibromas. There are fewer studies assessing QoL in individuals with NF2. A qualitative study found 11 domains affecting QoL in patients with NF2: hearing, balance, functional function, vision, oral intake, future uncertainty, psychosocial, cognition, sexual activity, pain, and vocal communication. Additionally, one study in the United Kingdom and one in the United States reported lower SF-36 scores in NF2 patients compared to the general population. One study assessed 288 patients with NF2 and found worse scores on items reflecting dizziness and balance problems, hearing loss, and impact of NF2 on role and outlook on life.

Given the lack of studies assessing the QoL of patients with NF1 and NF2 in Canada, we conducted a cross-sectional study of QoL in patients attending an academic clinic for adults with neurofibromatoses. We hypothesized that patients with NF1 and NF2 have a low QoL compared to the Canadian general population. We also hypothesized that specific disease manifestations, such as disease visibility and pain in NF1, and hearing loss in NF2, would correlate with overall QoL.

**Importance of the Study**

There is limited data on the quality of life of individuals with NF1 in Canada. In this cohort of young individuals, we found a high number of individuals who were unemployed or on disability. We also found reduced quality of life in NF1 and NF2 patients, and together these findings show the high burden of NF1 and NF2. In both conditions, the main factor affecting the quality of life was pain. We also found that a large number of individuals with NF1 and NF2 reported anxiety or depression. In addition, in NF1, self-perceived physical appearance—rather than visibility rated by a clinician—was the main predictor of mental well-being. Our findings highlight the importance of multidisciplinary care for people with NF1 and NF2, including assessing mental health and pain.

**Methods**

This is a cross-sectional study of patients attending the Elisabeth Raab Neurofibromatosis Multidisciplinary Clinic at Toronto General Hospital, between January 2016 and December 2017. We invited all adults who meet the clinical diagnostic criteria and/or genetically confirmed NF1 and NF2 to participate. We excluded from the study individuals unable to complete the questionnaires (eg, language barrier or limited literacy). The University Health Network research ethics board approved the study, and all participants provided written informed consent.

The attending clinician completed a standardized form for clinical manifestations of NF1 or NF2, including a family history of NF, genetic testing, known plexiform neurofibromas (either visible on examination by MRI), presence of spinal and brain tumors, other malignancies, and history of MPNSTs. We did not ask clinicians to specify if the plexiforms were diagnosed by imaging or examination, and it was a yes/no question. For individuals with NF1, the clinicians also rated the disease visibility using the Ablon visibility index. In this measure, patients are assessed while fully dressed, and visibility ranges from 1—mild, no visible tumors outside normal clothing areas to 3—indicating numerous visible tumors in the face or neck, or visible limp. For NF2, the physicians also completed the House and Brackmann facial nerve scale that rates facial nerve impairments from 1—normal symmetric function to 6—indicating complete paralysis. Finally, the physicians rated the hearing of NF2 patients, based on the last audiogram, using a 5-item Likert scale ranging from normal hearing to profound hearing loss.

The patients completed several questionnaires, including demographic data (age, sex, employment, and educational status), and health-specific measures described below.

**Generic Measures**

**SF-36:** This is a 36-item generic QoL measure that has normative data for the Canadian population. The SF-36 has 8 domains: physical functioning, role physical, bodily pain, general health perception, energy/vitality, social functioning, role emotional, and mental health. Additionally, the physical health domains are summarized in a physical score (PCS) and the mental domains in a mental score (MCS). Lower scores indicate lower QoL. The SF-36 has been widely used and validated in the Canadian population, with available normative data.

**EQ-5D-5L:** This is a 5-item multi-attribute questionnaire. The EQ-5D-5L dimensions are mobility, usual activities,
self-care, pain, and depression/anxiety, each with 5 response options. The EQ-5D-5L can be scored as health utilities, where a score of 1 indicates perfect health and 0 indicates death; negative scores are possible, indicating states valued as worse than death. Additionally, the EQ-5D-5L has a visual analogue scale (VAS) for a direct valuation of general health, ranging from 0—worst possible health to 100—best possible health. This has been widely used and validated in Canada and we used a Canadian valuation algorithm to estimate the EQ-5D-5L utility scores.

**PROMIS pain interference short form 8a:** This is an 8-item questionnaire, assessing how pain affects social, cognitive, physical, and recreational activities. Raw scores are converted into T-scores, ranging between 40.7 and 77; higher scores indicate worse pain interference. This measure has been recommended for trials assessing pain in adults with NF1, although it has not been specifically validated in Canada.

**Disease-Specific Measures**

**PedsQL NF1 adult module:** This is a 74-item self-reported measure, specifically developed for NF1. The PedsQL NF1 module has 16 domains assessing physical, emotional, social, and cognitive functioning, as well as communication, worry, perceived physical appearance, pain and hurt, paresthesia, skin irritation, sensation, movement and balance, daily activities, fatigue, treatment anxiety, and sexual functioning. Each item is scored in a 5-option Likert scale ranging from 0—never to 4—almost always and then reverse-scored between 0 and 100. The domain scores are calculated as the average score for all the items in each domain, and a total score is obtained by calculating the average of all items. Higher scores indicate better QoL. To our knowledge, this measure has not been previously used or validated in Canada.

**NFTI-QoL:** This is an 8-item NF2-specific questionnaire. The items reflect balance, hearing, facial weakness, visual problems, mobility, role and outlook on life, pain, and anxiety/depression. Each item is scored on a 4-point Likert scale from 0 to 3, and the total score is the sum of all items. Higher scores indicate worse QoL. To our knowledge, there are no previous Canadian data for this measure.

**Statistical Analysis**

Continuous data are described as mean ± standard deviation, or median and interquartile range; categorical data are presented as number and proportion.

For the generic measures (SF-36, EQ-5D-5L, PROMIS pain interference), we compared the mean scores between NF1 and NF2 individuals using t tests. For the SF-36, we also compared the results to Canadian normative data.

For the PedsQL NF1, we calculated the mean score in each dimension as well as the total score. For the NFTI-QoL, we calculated the mean total score and also the median score for each item.

We tested the correlation coefficients between the different generic and disease-specific measures. Finally, we conducted multivariable regression analyses to study the relationship between the different clinical and demographic variables and QoL. Because we used different QoL measures, we decide a priori to build regression models for the SF-36 PCS, SF-36 MCS, and total PedsQL NF1 score. If enough patients were enrolled with NF2, we also planned to build a model for the NFTI-QoL. We chose the variables for the models based on clinical grounds and previous reports, and we tested all variables for collinearity and possible interactions. We removed variables that were highly collinear, and we retained interaction terms according to likelihood ratio tests. For each dependent variable, we chose the best performing model, comparing R² statistics and residuals. Final models were bootstrapped with 100 repetitions to account for overfitting.

All analyses were done with R statistical software version 3.5.1, and we considered P-values < .05 as significant. We used Bonferroni correction when appropriate.

**Results**

Between January 2016 and December 2017, we screened 292 individuals with NF1 and 46 with NF2. A total of 184 individuals agreed to participate, 162 (88%) had NF1 and 22 (12%) had NF2. The mean age was 33 ± 13 years in NF1 and 40 ± 15 years in NF2; the proportion of females was similar between groups: 89 (55%) in NF1 and 13 (59%) in NF2. Thirty-four (22%) of the individuals with NF1 reported being unemployed or receiving disability benefits and this was reported in 9 (45%) in the NF2 group. Detailed demographic and clinical data are described in Table 1.

Patients with NF1 and NF2 had significantly lower scores in all the domains in the SF-36 compared to the Canadian normative population at this age range (t test P < .005). In general, NF2 patients had lower scores than patients with NF1, although this difference was only significant for Social Functioning and General Health (P-values .02 and .016, respectively). The comparison of the SF-36 scores of the NF1 and NF2 participants in relation to Canadian normative data is shown in Figure 1, and the specific SF-36 scores are given in Supplementary Table 1.

When analyzing the EQ-5D-5L, we found that a high proportion of patients reported some degree of pain/discomfort (66% for NF1 and 73% NF2, respectively) and anxiety/depression (61% and 68% for NF1 and NF2, respectively). The distribution of affected EQ-5D-5L scores is shown in Figure 2. The mean EQ-5D-5L VAS score was 74.5 ± 23 for NF1 patients and 64.2 ± 21 for NF2 (P-value .05). The mean EQ-5D-5L health utility score was 0.73 ± 0.24 for NF1 and 0.65 ± 0.25 for NF2 patients (P-value .16).

The PedsQL NF1 domains had less than 10% missing values, with the exception of the sexual domain that was missing in 20 (18%) of the patients. We obtained total PedsQL NF1 scores for 153 patients. Cronbach’s alpha for the PedsQL NF1 was 0.96. The PedsQL NF1 domains with the lowest scores (worse QoL) were perceived physical appearance, worry, cognitive, emotion, fatigue, and pain. Supplementary Table 2 shows the mean PedsQL scores by domain.

When looking at the NFTI-QoL, we only had one missing item in one patient, and we could obtain total scores for all
patients; Cronbach's alpha was 0.87. The items with highest (worse) scores were hearing (median 2, range 1–3) and outlook on life (median 2, range 0–3); these items, as well as the item on balance, had the lowest floor effects. The total NFTI-QoL had moderate to high correlations with the EQ-5D-5L utility score ($r = -0.65, CI: -0.86, -0.26, P = .003$), and the SF-36 MCS ($r = -0.63, CI: -0.85, -0.23, P = .004$). The distribution of item scores is shown in Supplementary Figure 1.

The PROMIS pain interference scores had moderate to high correlations with the SF-36 PCS, EQ-5D-5L health utilities, global health VAS, and the NFTI-QoL pain item. When analyzed separately by type of NF, the correlation between pain interference and health utilities was $-0.70$ (CI: $-0.77, -0.61, P < .001$) for NF1 and $-0.90$ (CI: $-0.96, -0.78, P < .001$) for NF2, as shown in Figure 3. The correlation matrix can be found in Table 2.

With 162 NF1 patients, we could fit regression models with up to 16 variables, using the common rule of thumb of 10 patients per variable; however, we aimed at a maximum of 10 variables to avoid overfitting and to test interaction and nonlinear terms. Given the small number of NF2 patients, we did not perform regression analysis in this group. The final model for the SF-36 PCS had age, sex, pain interference score, known plexiform neurofibroma, known spinal tumor, optic glioma, history of MPNST, and history of other cancers, with $R^2: 0.60$ and $P < .001$. For the SF-36 MCS, the final model had age, sex, pain interference score, known plexiform neurofibroma, optic glioma, history of MPNST, other cancers, employment status, marital status, and perceived physical appearance score, with $R^2: 0.36$ and $P = .0003$. For the PedsQL model, the variables were sex, age, pain interference score, plexiform neurofibroma, optic glioma, MPNST, and other cancers, with $R^2: 0.44$ and $P < .0001$. Worse pain interference scores and older age were significantly associated with worse SF-36 PCS, while worse perceived physical appearance and being divorced were associated with worse SF-36 MCS. For the PedsQL scores, being female, older, and with higher pain interference scores, was associated with worse QoL. Regression estimates for SF-36 PCS and MCS are given in Table 3, and regression estimates for the PedsQL are given in the Supplementary Material.

Discussion

We found that patients with NF1 and NF2 attending a tertiary academic center in Canada have reduced QoL, and this finding was consistent across the different QoL measures used.

This cohort had low employment rates, 49% in NF1 and 50% in NF2. These are lower than the employment rates for the general Canadian population at this age range, which was 83% in 2018. This provides indirect evidence of the social impact of NF1 and NF2, with only half of the individuals participating in the workforce. This is particularly striking as our cohort was young, although it may also reflect more severe patients seen at a tertiary center.

Additionally, our NF1 population had overall a higher (worse) scores were hearing (median 2, range 1–3), and outlook on life (median 2, range 0–3); these items, as well as the item on balance, had the lowest floor effects. The
or completed university program. This could be due to the exclusion of individuals who could not complete the questionnaires, for example, due to low literacy or language barriers, thus resulting in selection bias toward those with higher education levels. Additionally, it is possible that individuals with learning difficulties would choose not to answer a long questionnaire, such as in this study. Given that this cohort was in average well educated, the lower

or completed university program. This could be due to the exclusion of individuals who could not complete the questionnaires, for example, due to low literacy or language barriers, thus resulting in selection bias toward those with higher education levels. Additionally, it is possible that individuals with learning difficulties would choose not to answer a long questionnaire, such as in this study. Given that this cohort was in average well educated, the lower
employment rate is unlikely due to learning difficulties and more likely due to physical disabilities, chronic pain, and mental health problems. In our cohort, 16% of patients with NF1 and 25% with NF2 reported being on disability; this is higher than the approximately 5% of residents of the province of Ontario receiving government disability benefits in 2017. Additionally, individuals with NF1 may face discrimination based on the cutaneous manifestations of the disease, which may also affect employment rates.

In our study, and using the SF-36, both NF1 and NF2 patients had significant lower scores in all the domains, compared to the Canadian general population. This is in keeping with the findings of previous studies in different countries such as France, Italy, and the United States. While there was a trend toward lower scores in NF2, we only found significant differences between NF1 and NF2 patients in social functioning and general health. This is in contrast to the findings of Merker et al., who found that the mental component score was more affected in NF1 patients, while NF2 patients had lower scores in the physical component. However, our NF2 cohort was considerably smaller than the NF1 group, and this could

---

**Table 2.** Pearson Correlation Coefficients of the Total PedsQL Scores, Pain Interference, EQ-5D-5L, and SF-36 Scores

|                      | PedsQL-NF1 total score | PROMIS pain interference | EQ-5D-5L utilities | EQ-5D-5L VAS | SF-36 PCS | SF-36 MCS |
|----------------------|------------------------|--------------------------|-------------------|-------------|-----------|-----------|
| PedsQL total score   | 1.00                   |                          |                   |             |           |           |
| PROMIS pain interference | -0.58 (-0.68, -0.47) | 1.00                     |                   |             |           |           |
| EQ-5D-5L utilities   | 0.57 (0.46, 0.68)      | -0.70                    | 1.00              |             |           |           |
| EQ-5D-5L VAS         | 0.41 (0.26, 0.54)      | -0.53 (-0.63, -0.42)     | 0.47 (0.34, 0.58) | 1.00        |           |           |
| SF-36 PCS            | 0.63 (0.52, 0.72)      | -0.68 (-0.76, -0.59)     | 0.60 (0.49, 0.69) | 0.47 (0.34, 0.58) | 1.00 |           |
| SF-36 MCS            | 0.49 (0.36, 0.61)      | -0.23 (-0.37, -0.08)     | 0.32 (0.17, 0.45) | 0.20 (0.04, 0.35) | 0.15 (-0.00, 0.30) | 1.00 |

MCS, mental component score; PCS, physical component score; VAS, visual analogue scale. Bonferroni corrected P-value = .003.

---

**Figure 3.** Correlations between pain interference scores and EQ-5D-5L utility scores in individuals with (A) NF1 and (B) NF2. There were high correlations between pain interference scores and health utilities for both NF1 and NF2 patients, indicating that pain is a major driver of QoL in individuals with NF.
affect the likelihood of finding a statistically significant difference.

Using the EQ-5D-5L, we found a high prevalence of self-reported pain in N1 and NF2 patients. Importantly, pain interference was the main driver of QoL both for NF1 and NF2, demonstrated by the high correlations between pain interference and QoL scales. In the case of NF1, multivariable analyses showed that pain interference was one of the main variables affecting the physical component of the SF-36, as well as total PedsQL scores. Previous studies have shown that pain interference affects QoL in patients with NF1 and plexiform neurofibromas, but our study shows that pain is widely prevalent and clinically important in patients with NF1, regardless of the presence of plexiform neurofibromas, as shown in our regression models. Due to the numerous questionnaires, and to minimize patient burden, we did not specifically ask about the sources of pain, so we could not stratify by pain cause, and this was beyond the scope of this study. Additionally, we also found that pain is a prevalent problem for individuals with NF2, with high impact on overall QoL. Pain in NF2 has not been as widely reported as in NF1, but there are potential causes including NF2-related neuropathy, which has been described in up to 60% of NF2 individuals. Additionally, during development of the NFTI-QoL, patient focus groups identified pain as a relevant domain for NF2-related QoL. Further studies in a larger population of individuals with NF2 are needed to better understand pain prevalence and its causes in individuals with NF2.

We also found a high prevalence of self-reported anxiety and depression, and this is in keeping with previous studies done in different countries and healthcare systems. For example, a survey of 498 adults with NF1 showed a prevalence of depression of 55%, similar to our findings. Another survey of adults with NF1, NF2, and Schwannomatosis also found a high prevalence of depression, up to 46%. Considering the high prevalence of mental health disorders in this and other studies, routine assessment of patients with NF1 and NF2 should probably include screening for depression and related disorders. These patients may also benefit from new interventions, such as resilience training through videoconference, that have shown to be feasible and effective in improving QoL in individuals with NF1 and NF2.

In our study, the main predictors of the mental component of the SF-36, which reflect mental health related QoL, were perceived physical appearance (subscore of the PedsQL NF1 module; married/partner and single, compared to being divorced; employed, unemployed, and other employment, compared to being on disability. In our study, the main predictors of the mental component of the SF-36, which reflect mental health related QoL, were perceived physical appearance (subscore of the PedsQL NF1 module; married/partner and single, compared to being divorced; employed, unemployed, and other employment, compared to being on disability. PCS, physical component score; MCS, mental component score. MPNST, malignant peripheral nerve sheath tumor (yes/no); perceived physical: perceived physical appearance subscore, from PedsQL NF1 module; married/partner and single, compared to being divorced; employed, unemployed, and other employment, compared to being on disability.

Table 3. Regression Estimates for the SF-36 Physical and Mental Component Scores in NF1

| SF-36 PCS Model | SF-36 MCS Model |
|-----------------|-----------------|
|                 | Estimate | SE  | P-value | Estimate | SE  | P-value |
| Intercept       | 89.4     | 5.3 | <.0001* | Intercept | 25.73 | 12.7 | .04* |
| Sex             | 0.37     | 1.98 | .85 | Sex      | 0.09 | 2.50 | .97 |
| Age             | −0.15    | 0.07 | .04 | Age      | 0.06 | 0.09 | .54 |
| Pain interference | −0.68   | 0.09 | <.0001* | Pain interference | −0.11 | 0.12 | .39 |
| Known plexiform | 1.40     | 1.98 | .48 | Known plexiform | 2.26 | 2.29 | .33 |
| Optic glioma    | −1.33    | 2.90 | .62 | Optic glioma | 1.19 | 3.15 | .70 |
| MPNST           | 2.21     | 1.98 | .57 | MPNST    | 1.98 | 4.54 | .66 |
| Other cancers   | −6.40    | 3.22 | .05 | Other cancers | −5.35 | 3.43 | .12 |
| Spinal tumor (yes/no) | −1.65 | 1.98 | .41 | Perceived physical | 0.13 | 0.04 | .0003* |
| Employed        | −1.57    | 3.4  | .64 | Employed | 1.35 | 3.6  | .5 |
| Unemployed      | 1.36     | 4.8  | .77 | Other employment | 1.36 | 4.8  | .77 |
| Married/partner | 17.5     | 7.8  | .028* | Married/partner | 17.1 | 7.73 | .03* |

PCS, physical component score; MCS, mental component score. MPNST, malignant peripheral nerve sheath tumor (yes/no); perceived physical: perceived physical appearance subscore, from PedsQL NF1 module; married/partner and single, compared to being divorced; employed, unemployed, and other employment, compared to being on disability. *P < .05.
body image image scores in women with NF1 compared to men with NF1,36; our regression model found that women had worse scores in the PedQoL NF1 module (P = .026), but not in the SF-36 scores. It is possible that this reflects the lack of sensitivity of generic measures to assess body image and self-perceived appearance. Further analysis of these data by gender might provide more insight into any gender-based differences.

In the case of the NF2-specific measure, we found that hearing, balance, and outlook on life were the most affected items. This is similar to the cohort where NFTI-QoL was developed,29 as well as a US cohort that used this measure.36 There was a high correlation between the NFTI-QoL total scores and scores on generic measures such as the EQ-5D-5L and SF-36, supporting validity for the Canadian population. However, these findings are limited due to the small number of participants. Additionally, with only 8 items, the NFTI-QoL may miss other areas relevant to NF2 patients.

In addition to the small number of NF2 participants, our study was conducted in a single, tertiary academic center. Therefore, our findings may be biased toward patients who have more severe disease, who tend to be followed at specialty care centers and may not be applicable to individuals with milder disease followed in the community. Additionally, we enrolled approximately 50% of the patients screened for the study, with selection bias toward those with higher educational attainment and literacy. Unfortunately, there are no population-based data in Canada regarding individuals with NF1 and NF2, so we do not know how well our sample reflects the overall universe of Canadians living with NF1. Additionally, there are many other factors that affect QoL, such as socioeconomic status, which we did not specifically address in this study. Strengths of our study are the use of several generic and disease-specific measures that capture different aspects of QoL.

In summary, we found that adult patients with NF1 and NF2 attending a specialty clinic in Canada have reduced QoL compared to the general Canadian population. There is a high prevalence of pain and anxiety/depression in NF1 and NF2 patients. In NF1, perceived visibility is a major driver of mental well-being, while pain is a major driver of physical health. Our findings highlight the importance of multidisciplinary management of individuals with NF1 and NF2, and we suggest screening for pain and depression in routine assessments of individuals with NF. Additionally, the impact of skin manifestations in NF1 patients and its effect on mental health should be assessed individually in each patient, as self-perceived body image may differ from the skin manifestations seen by an examiner.

**Supplementary Data**

Supplementary data are available at Neuro-Oncology online.

**Keywords**

EQ-5D-5L | NF1 | NF2 | pain interference | quality of life

---

**References**

1. Fender RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 2007;44(2):81–88.
2. Evans DGR, Wallace A, Kaufman D, eds. Neurofibromatoses. Basel, Switzerland: Karger Medical and Scientific Publishers; 2008:154.
3. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life: a conceptual model of patient outcomes. JAMA. 1995;273(1):59–65.
4. Kodra Y, Giustini S, Divona L, et al. Health-related quality of life in patients with neurofibromatosis type 1. Dermatology. 2009;218(3):215-220.
5. Page PZ, Page GP, Ecosse E, Korf BR, Leplege A, Wolkenstein P. Impact of neurofibromatosis 1 on quality of life: a cross-sectional study of 176 American cases. Am J Med Genet A. 2006;140(18):1893–1898.
6. Vranceanu AM, Merker VL, Park E, Plotkin SR. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature. J Neurooncol. 2013;114(3):257–262.
7. Merker VL, Bredella MA, Cai W, et al. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis. Am J Med Genet A. 2014;164A(6):1431–1437.
8. Wolters PL, Burns KM, Martin S, et al. Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life. Am J Med Genet A. 2015;167A(9):2103–2113.
9. Cossetti MK, Golfinos JG, Roland JT Jr. Quality of life (QoL) assessment in patients with neurofibromatosis type 2 (NF2). Otolaryngol Head Neck Surg. 2015;153(4):599–605.
10. Neary WJ, Hillier VF, Flute T, Stephens SDG, Ramsden RT, Evans DGR. The relationship between patients’ perception of the effects of neurofibromatosis type 2 and the domains of the short form-36. Clin Otolaryngol. 2010;35(4):291–299.
11. Merker VL, Bergner AL, Vranceanu AM, Muzikansky A, Slattery W 3rd, Plotkin SR. Health-related quality of life of individuals with neurofibromatosis type 2: results from the NF2 natural history study. Otol Neurotol. 2016;37(5):574–579.
12. Fender RE, Shaw A, Evans DG, et al. Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2. J Neurol. 2014;261(5):983–989.
13. Stumpf D. Consensus development conference of neurofibromatosis. Arch Neural. 1988;45:575–578.
14. Smith MJ, Bowers NL, Bulman M, et al. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis. Neurology. 2017;88(1):87–92.
15. Ablon J. Gender response to neurofibromatosis 1. Soc Sci Med. 1996;42(1):99–109.
16. House WE, Brackmann DE. Facial nerve grading system. Otolaryngol Head Neck Surg. 1985;93:184–193.

---

**Acknowledgments**

Disclosures: G.H.-J., R.K., S.S., G.Z., and V.B. report no disclosures. C.B. reports consulting fees from Akcea, Takeda, and Alexion and grant support from Octapharma and Grifols. None of these are related to this study.
17. World Health Organization. Primary Ear and Hearing Care Training Resource. Geneva, Switzerland: WHO Press; 2006.
18. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey. Boston: Quality Metric; 1993.
19. Hopman WM, Towheed T, Anastassiades T, et al. Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group. Can Med Assoc J. 2000;163(3):265–271.

20. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37(1):53–72.
21. Xie F, Pullenayegum E, Gaebel K, et al.; Canadian EQ-5D-5L Valuation Study Group. A time trade-off-derived value set of the EQ-5D-5L for Canada. Med Care. 2016;54(1):98–105.
22. Amtmann D, Cook KP, Jensen MP, et al. Development of a PROMIS item bank to measure pain interference. Pain. 2010;150(1):173–182.
23. Wolters PL, Martin S, Merker VL, et al.; REINS International Collaboration. Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials. Neurology. 2016;87(7 suppl 1):S4–S12.
24. Nutakki K, Hingtgen CM, Monahan P, Varni JW, Swigonski NL. Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity. Health Qual Life Outcomes. 2013;11:21.

25. Hornigold RE, Golding JF, Leschziner G, et al. The NFTI-QOL: a disease-specific quality of life questionnaire for neurofibromatosis 2. J Neurol Surg B Skull Base. 2012;73(2):104–111.
26. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2007.
27. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression and Survival Analysis. New York: Springer; 2001.
28. OECD. Employment rate by age group (indicator). doi: 10.1787/084f32c7-en. https://data.oecd.org/emp/employment-rate-by-age-group.htm#indicator-chart. Accessed November 11, 2019.
29. Doser K, Kenborg L, Andersen EW, et al. Educational delay and attainment in persons with neurofibromatosis 1 in Denmark. Eur J Hum Genet. 2019;27(8):857–868.
30. Social Assistance Analytics Unit. Policy Research & Analysis Branch. Social Policy Development Division. Ministry of Community and Social Services. Ontario Social Assistance Monthly Statistical Report. Ontario Disability Support Program. https://www.mcss.gov.on.ca/documents/en/mcss/social/reports/ODSP_EN_2017-12.pdf. Accessed November 11, 2019.
31. Wolters PL, Martin S, Merker VL, et al.; REINS International Collaboration. Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials. Neurology. 2013;81(21 suppl 1):S6–14.
32. Sperfeld AD, Hein C, Schröder JM, Ludolph AC, Hanemann CO. Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2. Brain. 2002;125(Pt 5):996–1004.
33. Cohen JS, Levy HP, Sloan J, Dariotis J, Biesecker BB. Depression among adults with neurofibromatosis type 1: prevalence and impact on quality of life. Clin Genet. 2015;88(5):425–430.
34. Wang DL, Smith KB, Espana S, et al. Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome. Genet Med. 2012;14(12):977–982.
35. Vranceanu AM, Riklin E, Merker VL, Macklin EA, Park ER, Plotkin SR. Mind-body therapy via videoconferencing in patients with neurofibromatosis: an RCT. Neurology. 2016;87(8):806–814.
36. Granström S, Langenbruch A, Augustin M, Mautner VF. Psychological burden in adult neurofibromatosis type 1 patients: impact of disease visibility on body image. Dermatology. 2012;224(2):160–167.
37. Gardner RM. Methodological issues in assessment of the perceptual component of body image disturbance. Br J Psychol. 1996;87(Pt 2):327–337.
38. Shukla A, Hsu FC, Slobogean B, et al. Association between patient-reported outcomes and objective disease indices in people with NF2. Neurol Clin Pract. 2019;9(4):322–329.